Carisma Therapeutics Announces Adjournment of Annual Meeting of Stockholders
Carisma Therapeutics (Nasdaq: CARM), a clinical-stage biopharmaceutical company, announced the adjournment of its annual stockholder meeting on June 13, 2024, due to technical difficulties.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Carisma Therapeutics (Nasdaq: CARM), a clinical-stage biopharmaceutical company, announced the adjournment of its annual stockholder meeting on June 13, 2024, due to technical difficulties. The meeting will reconvene virtually on June 14, 2024, at 10:00 a.m. Eastern Time. Stockholders can attend online, vote electronically, and submit questions via a virtual audio web conference.
Positive
- The meeting will reconvene promptly, minimizing delays for shareholders.
- Stockholders retain the ability to vote and participate virtually, ensuring continued engagement.
Negative
- Technical difficulties disrupted the planned meeting, potentially undermining investor confidence.
- No business was conducted during the originally scheduled meeting, causing an operational delay.
Details
News Market Reaction – CARM
The recorded move for CARM in the trading session of this news was -2.56%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Meeting will be reconvened on Friday, June 14, 2024 at 10:00 a.m. Eastern Time
Carisma stockholders will be able to attend the virtual annual meeting online, vote their shares electronically and submit questions via the Internet by virtual audio web conference at https://meetnow.global/MAJJ4AY.
About Carisma
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in
Media Contact:
Julia Stern
(763) 350-5223
jstern@realchemistry.com
Investors:
Shveta Dighe
Head of Investor Relations
investors@carismatx.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-announces-adjournment-of-annual-meeting-of-stockholders-302172413.html
SOURCE Carisma Therapeutics Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.